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Pacing therapies for heart failure, which involve stimulating the
left ventricle, have come to occupy centre stage at interna-
tional cardiology conferences in the past 2 years. These types
of therapy are generally referred to as ‘biventricular pacing’ or
‘resynchronisation therapy’. They involve pacing the left ventri-
cle, generally in addition to the right ventricle and the right
atrium. The high level of interest is understandable, as the
prospect of a new therapy that may provide significant symp-
tomatic benefit to patients with drug refractory heart failure is
clearly desirable. The therapy presents cardiologists who
implant pacemakers with an enticing new technical challenge,
making biventricular pacing even more attractive.
This article aims to review the background to this research, to
analyse the published and recently announced trial results,
and to address the two most pressing questions about biven-
tricular pacing. If it works, why does it work? Which heart
failure patients will it benefit?
Background
Pacing and atrioventricular delay
In the 1980s, interest in pacing therapy for heart failure
largely revolved around manipulation of the atrioventricular
(AV) delay in patients with heart failure who were implanted
with dual-chamber pacemakers using right atrial and right
ventricular leads. Shortening the AV delay appeared to be
beneficial in patients with first-degree AV block and in those
with Doppler evidence of presystolic mitral regurgitation [1,2].
Individual patients appeared to show marked clinical improve-
ment, but no benefit was found in patients with New York
Heart Association (NYHA) class III or IV heart failure in long-
term follow-up in controlled, randomised trials [3,4].
Multisite pacing
Early reports of biventricular pacing involved epicardial left
ventricular (LV) leads. In 1994, Cazeau et al. reported a
patient with refractory heart failure who had responded to
four-chamber pacing [5]. In 1995, Foster et al. investigated
pacing following coronary artery bypass graft, using different
combinations of cardiac chambers with epicardial leads [6].
The authors found that maximal haemodynamic benefit was
derived from a combination of atrial and biventricular pacing.
It was known that patients with heart failure frequently had
dysynchronous contraction of the cardiac chambers [7]. The
underlying concept of resynchronisation therapy was that the
efficiency of the heart as a pump would be increased if the
start of systole could be synchronised by simultaneously
pacing the two atria, followed by the ventricles.
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Abstract
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This hypothesis was tested in ‘on-table’ haemodynamic
studies. The tests consistently showed increases in cardiac
output and decreases in pulmonary capillary wedge pressure
when patients were switched from right ventricular pacing to
simultaneous biventricular pacing (Table 1) [8–10].
In 1998, Daubert et al. reported in the journal PACE that the
LV free wall could be effectively paced on a long-term basis by
a transvenous technique [11]. The authors reported introduc-
ing a unipolar lead via the coronary sinus and positioning the tip
in an epicardial vein on the lateral wall of the left ventricle as
part of a permanent pacing system (Fig. 1). This raised the pos-
sibility of delivering the haemodynamic benefits demonstrated
in the acute on-table studies as a permanent therapy without
the morbidity associated with thoracotomy techniques. Daubert
et al. christened this new approach to the treatment of patients
with heart failure ‘resynchronisation therapy’.
A number of trials were initiated from this point onwards.
Some were observational studies of series of patients under-
going biventricular pacing [12,13]. Other trials involved ran-
domisation to biventricular pacing or no pacing — single
blinded, as in the Multisite Stimulation in Cardiomyopathies
(MUSTIC) trial [14], or double blinded, as in the Multicenter
InSync Randomized Clinical Evaluation (MIRACLE) trial [15].
Recent trial results
Some of the results of these recent trials have been published
in peer-reviewed journals, others have been reported as
abstracts, and some have only recently been announced at
‘late breaking trial results’ sessions at international meetings.
The data currently available are presented in Table 2. It should
be emphasised that some of this is preliminary data, which
may change after the follow-up is completed in these studies
Although much of this data has not yet been peer reviewed,
and may only reflect preliminary findings before follow-up, it is
clear that there is a high degree of consistency in the data so
far available from trials. Of recent interest were the results
from the MIRACLE trial presented by William Abraham at the
North American Society of Pacing and Electrophysiology
(NASPE) 2001 meeting. Both the patients and the physicians
monitoring the progress of patients in the study were blinded
to the pacing mode. This would seem to rule out the possibil-
ity that the benefits seen with pacing in the biventricular
mode might all have been due to the increased expectation of
good performance by the supervising physicians. Overall, it
seems very likely that a real effect is being observed.
The average magnitude of the effect is modest, although very
helpful, in terms of clinical improvement. The situation is almost
certainly one in which some patients are showing marked clini-
cal benefit, balanced by other patients with very little benefit.
In the absence of a clear understanding of the mechanisms
by which clinical benefit is being achieved, biventricular
pacing will remain a relatively crude therapy, dictated primar-
ily by what is feasible rather than by aiming for a planned and
individually tailored electromechanical goal.
Theories underlying mechanisms: why does
biventricular pacing work?
Optimisation of AV delay 
Patients with heart failure and PR prolongation may be a sub-
group who benefit from optimisation of atrioventricular (AV)
Table 1
On-table haemodynamic results of biventricular pacing [10]
AAI DDD Biventricular paced
Cardiac index (l/min/m2) 2 ± 0.5 2.4 ± 0.6 2.7 ± 0.7
Pulmonary capillary wedge pressure (mmHg) 27 ± 9 24 ± 5 22 ± 8
Figure 1
Pacing lead positions in transvenous biventricular pacing. Endocardial
leads are positioned in the right atrium and right ventricle, and the left
ventricle is paced via a lead passed through the coronary sinus to an
epicardial vein on the free wall of the left ventricle. 
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delay. This optimization of the AV delay is thought to correct
adverse compression of the diastolic filling time and to reduce
presystolic mitral regurgitation [1,2]. Such patients may obtain
this haemodynamic gain from adjustment to AV delay as part
of a biventricular pacing system, so this could contribute to
clinical improvement in such patients. This aspect of biventric-
ular pacing is likely to play a part in a small subgroup only.
Reduction in systolic mitral regurgitation
Reports of reduced mitral regurgitation with biventricular
pacing appeared shortly after original descriptions of the
transvenous technique [16]. This mechanism was investigated
as part of the MIRACLE study. The preliminary presentation of
results at the NASPE 2001 meeting [15] reported a reduction
in the mitral regurgitation jet area from 7 to 4 cm2 in the biven-
tricular paced patients from baseline to 6 months, whereas the
control group showed no change. Other investigators have
observed similar reductions in the mitral jet area [17]
One possible explanation for this improvement in patients
with so-called functional mitral regurgitation may be the
change in the activation sequence of the LV chamber and
papillary muscles. Contraction is normally from apex to base,
but with biventricular pacing this pattern is reversed and the
base contracts before the apical LV myocardium. This
change may be consequent on the typically basal position of
the LV lead in the part of the posterolateral LV vein close to
the AV ring. This reversal of the contraction pattern has been
demonstrated using radionucleotide angioscintigraphy in
patients with dilated cardiomyopathy, and appeared to corre-
late with long-term benefits from biventricular pacing [18].
Increased efficiency of systolic function
It has been proposed that, because of the long delay in acti-
vation time from septal depolarisation to depolarisation of the
LV free wall, contractile patterns can arise where the septal
muscle is starting to relax as the left free wall enters systole.
This is likely to result in reduced contractile efficiency, and
tagged magnetic resonance angiography has confirmed the
wobbling motion of the LV cavity in the setting of severe
dilated cardiomyopathy and LV dilatation [19].
Correction of this problem by biventricular stimulation resulting
in simultaneous activation of the septal and free wall muscle
appears to result in increased arterial pulse pressure
(increased by 18%) and LV dP/dT (increased 43%), with a
decrease in the arteriovenous oxygen saturation (4% lower
with biventricular pacing). This is a unique observation in
patients with heart failure. All therapies capable of increasing
systolic function have previously been associated with
increased myocardial oxygen consumption and, in long-term
follow-up, increased mortality. This is therefore an exciting initial
observation requiring replication and further investigation.
Diastolic ventricular interaction
Another potentially important mechanism is the reversal of
adverse diastolic ventricular interaction by biventricular
pacing. Patients with heart failure and left bundle branch
block have a tendency for LV diastole to start markedly later
than that in the right ventricle. Where the atrial filling pres-
sures are raised and the heart is dilated, the pericardium will
rapidly come close to its distensible limit during ventricular
filling. The tendency is for the right ventricle to fill first,
Table 2
Summary of the trial results currently reported
Number Increase in Improved Decreased 
of Randomised Increase in VO2 max/ejection quality hospital 
Trial patients comparison 6 min walk fraction of life admissions
Bordeaux series [13] 47 No Not done No significant Functional class Not stated
change improvement
InSync [12] 103 No 50 m (P = 0.01) Not stated 45% Not done
PATH-CHF [30] 42 Yes 60 m VO2 max Increased Not stated
increased 23%
MUSTIC (SR) [14] 58 Yes 23% (P < 0.001) 8% (P < 0.03) 32% (P < 0.001) 3 admitted during 
biventricular pacing 
versus 9 during no pacing
MIRACLE [15] 370 Yes (patients 35 m (P = 0.04) Awaited Small but 233 days (biventricular) 
and physicians) significant versus 621 days (control)
(P < 0.002) over 6 months
CONTAC CD 460 (33% NYHA Yes No significant VO2 max 9% increase; No significant Not stated
class II) change LV diameter 4 mm change
decrease (P = 0.001)
CONTAC CD, information from oral presentations at the North American Society of Pacing and Electrophysiology 2001 meeting; MIRACLE,
Multicenter InSync Randomized Clinical Evaluation; MUSTIC, Multisite Stimulation in Cardiomyopathies; PATH-CHF, Pacing Therapies for
Congestive Heart Failure; NYHA, New York Heart Association; LV, left ventricular.
expanding within the pericardial sac, resulting in an increased
baseline pressure within the space enclosed by the pericar-
dial sac at the start of LV filling. This results in decreased LV
filling, as the amount of filling will be dependent on the pres-
sure difference between the left atrial pressure and the pres-
sure within the LV cavity. This pressure difference is
determined by the sum of the hydrostatic pressure of blood
within the left ventricle and the pressure exerted externally on
the walls of the LV by the pre-existing pressure within the
pericardial space. Pacing the left ventricle before the right
reverses this problem as the LV enters diastole first and starts
to fill when the pressure in the pericardial space is at the
lowest point. This mechanism is therefore an argument for LV
pacing rather than biventricular pacing, and some groups
have tested the hypothesis that this is the principle mecha-
nism of benefit in LV pacing without stimulation of the right
ventricle [20,21].
Anti-arrhythmic effects
Some preliminary data suggest that, alongside improvement
in ventricular function, there may be a beneficial effect on ven-
tricular arrhythmias. The Ventak CHF study [22] randomised
32 patients to 3 months of either no pacing or biventricular
pacing. Thirty-four percent of patients without biventricular
pacing over this period experienced at least one ventricular
tachyarrhythmia; in contrast, only 16% of patients with biven-
tricular pacing had an episode of ventricular tachyarrhythmia.
Walker et al. studied ventricular ectopic frequency in the dif-
ferent pacing modes in heart failure patients who had under-
gone biventricular pacing, and have reported similar evidence
of benefit [23].
Effects on mortality
The mortality rate in trials such as the MUSTIC trial was lower
than might have been predicted for NYHA class III–IV heart
failure patients. A mortality rate of 7.5% over 7.5 months was
reported for patients with sinus rhythm. There are now large-
scale trials underway, such as the Cardiac Resynchronisation
in Heart Failure trial, which are powered and designed to
answer the question whether there is a significant mortality
benefit from biventricular pacing additional to the combined
mortality benefit from optimised heart failure drug therapy.
Myocardial remodelling
Over the past decade there has been intensive investigation,
at a molecular level, of the underlying myocardial environment
in patients who have molecular processes leading to progres-
sive, adverse remodelling. It may be that a change in wall
stress and energy consumption, of even a small degree,
might be enough to halt or reverse a downhill slide, and
reverse adverse patterns of gene expression. As such,
remodelling is likely to involve different processes at a cellular
level; patients with completely different pathologies, such as
ischaemic heart disease or dilated cardiomyopathy, may
respond very differently to the changes in the pump efficiency
likely to be achieved by biventricular pacing. While little infor-
mation exists in relation to any such modulation of molecular
processes by biventricular pacing, a direct effect on critical
influences on myocardial receptors such as sympathetic
nervous system activation has been documented [24].
In addition to different effects at a molecular level, it may also
be necessary in patients with ischaemic heart disease to
apply the therapy in a more individual regional fashion.
Patients who have suffered myocardial infarction in different
territories may have different wall motion and papillary muscle
problems.
Limitations to the technique
The most frustrating aspect of biventricular pacing is proba-
bly when it proves difficult to cannulate the coronary sinus os
with the guide sheath. This may be due to the limited shapes
of guide sheaths available and insufficient stiffness for place-
ment of the LV lead. This difficulty results in situations where
the coronary sinus can be cannulated with a diagnostic
catheter, such as an AL2, but when the sheath is advanced,
even when the locating catheter and guidewire are in the
coronary sinus, there is a tendency for the system to become
displaced. Approaches are being developed to mount a more
flexible-tipped sheath on a steerable guide similar to a
radiofrequency ablation catheter, which should help with this
problem in difficult cases where right atrial dilatation and dis-
tortion of the usual position is present.
Another area of difficulty is selecting the optimal vein for lead
placement. This has been made easier with leads deployed
using an angioplasty guidewire technique, although entry to
veins with an adverse angle onto the junction with the coro-
nary sinus is still a problem. This can require cannulation of
the side branch with a diagnostic catheter with a sharply
angled tip, such as a JR4, preferably in as flexible and soft a
version as possible, to avoid trauma to the vein. Once the
wire is placed, it may then be possible to steer the electrode
around the sharp bend. This technique is helped by reducing
the length of the diagnostic catheter for ease of manipulation.
Finally, problems with thresholds and phrenic nerve stimula-
tion can occur. Leads with narrow tips, which need to be
fixed by friction against the vein wall, can end up having to be
pushed too far towards the LV apex in large posterolateral
veins, causing phrenic nerve stimulation common in this site.
It is also possible that the loss of base to apex activation in
this situation may decrease the effectiveness of the tech-
nique. To counter this problem, in suitable veins of large
calibre, there are now leads that produce a preformed spiral
shape on stylet removal, allowing the lead to press against
the walls of a relatively large calibre vein.
Each procedure should ideally be planned once the coronary
sinus angiogram has been obtained. This requires a range of
electrodes to be available for each procedure. This approach







obtained prior to the procedure, as it is sometimes difficult to
predict which lead will achieve stability with good thresholds
in a suitable vein position.
Venous access may be difficult in some cases and a left sub-
clavian venogram may be valuable for imaging the vein on the
side of intended placement. It is helpful to check that a rea-
sonable sized vein without major anomalies is present before
embarking on either triple subclavian puncture or a combina-
tion of cephalic cannulation and venous puncture.
How widely applicable is the technique? 
Who will respond?
Estimates of the numbers of patients that may be eligible for
biventricular pacing have been based on the percentage of
symptomatic heart failure patients with broad QRS complexes
or other features associated with clinical benefit in trials. The
numbers have been estimated from district hospital [25] and
tertiary referral-based [26] populations at 10% and 14% of
heart failure patients, respectively. These estimates are neces-
sarily very speculative as there is little information yet available
to allow accurate identification and selection of patients likely
to achieve the best response from biventricular pacing.
The Bordeaux group found that non-responders were more
likely to be older, to have an underlying aetiology of ischaemic
heart disease, and to have no evidence of mitral regurgitation
[13]. Like some other groups who have reported recently (e.g.
the MIRACLE investigators) [15], the Bordeaux group found
no correlation between baseline QRS duration and clinical
response. There are, however, reports that responders have
narrower biventricular-paced complexes than do non-respon-
ders (i.e. 154 ± 17 ms versus 177 ± 26 ms), which may indi-
cate that benefit equates to more effective overall
resynchronisation of activation times in the ventricles [27].
The Baltimore group recently reported an analysis of parame-
ters predicting a positive response to biventricular pacing in
22 patients with dilated cardiomyopathy [28]. They made an
on-table assessment using a LV micromanometer and mea-
sured dP/dTmax during sinus rhythm and left free wall pacing.
The study reported that a baseline QRS duration >155 ms in
association with dP/dT max < 700 Hg/s predicted a percent-
age change of dP/dT max with LV pacing of greater than
25% and a percentage change in arterial pulse pressure of
greater than 10% with no false positives. This was an acute
study and the analysis needs to be examined in permanently
implanted patients.
Another technique that shows promise in identifying respon-
ders is Tissue Doppler Imaging (TDI) (or tissue velocity
imaging). In a recently reported study of 21 patients under-
going biventricular pacing, improvement in TDI measure-
ments of the synchrony of LV segment contraction was
associated with clinical improvement, exercise time improve-
ment and LV ejection fraction improvement. Patients without
improved TDI measurements showed no benefit from biven-
tricular pacing [29].
Aside from the question of identifying patients likely to
respond to biventricular pacing, there are also questions of
proper training in the technique, and availability of cardiac
catheter laboratory time. For the present, these factors may
play an important part in determining how widely the tech-
nique is applied. If an operating theatre with a C-arm is used
it can be difficult to achieve adequate left anterior oblique and
right anterior oblique projections for facilitating coronary
sinus entry and lead manipulation, because most pacing and
operating theatre tables have metallic sides that make
imaging in oblique planes difficult. Manoeuvrability of the C-
arm is also limited. In practice, the technique is likely to be
confined to those cardiac catheter laboratories that have the
very high level of sterility required to avoid infection in situa-
tions where the pre-pectoral wound may be open for 2 hours.
While the experienced operator will expect shorter operative
times, there will necessarily be a learning curve where, at first,
procedure times will be prolonged, taking up a whole morning
or afternoon session.
There is also the question of the cost of the systems. At
present in the UK a biventricular system is usually supplied for
a total cost of approximately £4500, which is about 50% more
than the cost of a standard dual-chamber system. While differ-
ent centres may be able to negotiate advantageous prices with
suppliers and while there are significant variations in the costs
of pacing systems in different countries, the increased cost is
likely to be a significant obstacle to increasing the availability of
this therapy in some health care environments.
Conclusions
Trials of biventricular pacing indicate a fairly consistent
pattern of symptomatic benefit in patients with NYHA class
III–IV heart failure. Effects on mortality will not be clearly
determined until the results of trials addressing this question
are reported in 3–4 years time. The technique is gradually
becoming easier to deliver and, in the absence of contradic-
tory or adverse trial results and in the absence of the emer-
gence of an alternative therapy for such patients, it is likely to
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